Baird Downgrades Achillion Pharmaceuticals To Neutral

Analysts at Baird downgraded

from Outperform to Neutral. The price target for Achillion Pharmaceuticals has been raised from $12 to $16. Achillion Pharmaceuticals shares have surged 356.93% over the past 52 weeks, while the S&P 500 index has gained 13.38% in the same period. Achillion Pharmaceuticals' shares climbed 9.01% to close at $15.49 yesterday.